Since we are going to talk about Spikevax we once again need to make it very clear that Spikevax and the Moderna COVID-19 Vaccine do have VERY IMPORTANT differences.
There is a significant legal distinction between products authorized under EUA and those fully licensed by the FDA. According to the FDA there is NO FDA APPROVED COVID VACCINE AVAILABLE IN AMERICA.
Specifically, under 21 U.S. Code Sec.360bbb-3(e)(1)(A)(ii)(III), “authorization for medical products for use in emergencies,” it is unlawful to deny someone a job or an education because they refuse to be an experimental subject. Instead, potential recipients have an absolute right to refuse EUA vaccines.
Notably, on Nov. 12, 2021, a federal judge rejected an argument by the U.S. Department of Defense, in defending the military’s vaccine mandate, that the Pfizer Comirnaty and Pfizer-BioNTech vaccines are “interchangeable.”
U.S. law also requires the EUA designation be used only when “there is no adequate, approved and available alternative to the product for diagnosing, preventing or treating such disease or condition.”
This means that, in legal terms, all EUA products should be withdrawn once alternative products have received full approval.
Perhaps the most significant legal distinction, however, pertains to the legal protections afforded vaccine manufacturers, depending on how their product is classified.
Under the 2005 Public Readiness and Preparedness (PREP) Act, EUA-approved vaccines enjoy a significant liability shield. Specifically, vaccine manufacturers, distributors, providers, and government officials involved in the policymaking, approval, and distribution process are immune from any legal liability.
Under such regulations, the only way an injured party can sue is if he or she can prove willful misconduct, and if the U.S. government has also brought an enforcement action against the party for willful misconduct.
No such lawsuit has ever succeeded.
Conversely, fully licensed vaccines, such as Spikevax and Comirnaty, do not have a liability shield, and are instead subject to the same product liability laws as other products.
This means the Spikevax and Comirnaty vaccines could expose pharmaceutical companies to significant financial claims if individuals injured by the vaccines chose to sue the vaccine makers. This is why they remain unavailable.
The rush to get COVID vaccines authorized for all ages — a ploy to avoid liability?
There’s another reason Pfizer and Moderna don’t want their fully licensed vaccines to be available yet — they’re waiting for the vaccines to be authorized, then licensed, for children as young as 6 months old.
Why? Because once a vaccine is fully licensed by the FDA, the only way its manufacturer can be shielded from legal liability is if the vaccine is added to the Centers for Disease Control and Prevention’s childhood vaccination schedule.
The National Childhood Vaccine Injury Act (NCVIA), passed into law in 1986, provides a legal liability shield to drugmakers if they receive full authorization for all ages and the vaccine is added to the mandatory schedule.
Reporting on the FDA’s approval of Spikevax, investigative journalist Jordan Schachtel wrote:
“Are Pfizer and Moderna waiting for full authorization for children’s shots to distribute Comirnaty and Spikevax to the masses? There’s plenty of litigators who have suggested that this is exactly what is going on in Big Pharma world.”
By creating the public perception that the Pfizer and Moderna EUA vaccines are fully approved, businesses, schools and other institutions are emboldened to impose vaccine mandates that violate existing law and allow the vaccines to be administered without informed consent.
It has also been argued that by relabeling the product, any previous data regarding vaccine injuries and side effects identified in association with the EUA vaccine are not counted in the safety studies for the approved vaccine.
FDA admits no safety data for Spikevax use among pregnant women or for Omicron
Beyond the legal questions raised by the FDA’s approval this week of Spikevax, the approval also raises safety questions.
For instance, the FDA admitted Spikevax was insufficiently tested on pregnant women, stating that “[a]vailable data on SPIKEVAX administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy.”
Furthermore, Spikevax was approved without having been tested for its ability to provide protection against the Omicron variant, which is reported to account for 99.9% of current U.S. COVID cases — it was approved only for providing protection against mutations that are no longer circulating.
And yet, the FDA cited the Omicron variant as the reason behind its decision to pull its EUA for monoclonal antibody products. The FDA claims that these products have not been shown to provide protection against the Omicron variant.
According to the CDC 99.9-100% of COVID cases are currently Omicron